KLF6 and hepatocellular carcinoma: In this study, we demonstrated that LCACs at concentrations ranging from 3.75 to 7.5 μmol/L, including LCAC-14:0, LCAC-16:0, LCAC-16:1, LCAC-18:0, LCAC-18:1, and LCAC-18:2, inhibit proliferation of human HCC cells via KLF6/p21 pathway.